How High Is the Success Rate for Stomach Cancer Surgery in 2026?

There is no single statistic called the "success rate" for stomach cancer surgery itself. Instead, national data showing treatment outcomes by stage can offer an answer. Among people diagnosed with stomach cancer in Korea between 2019 and 2023, the 5-year relative survival rate was 78.6% (National Cancer Registration Statistics 2019–2023).

Key Takeaways

• Korea's 5-year relative survival rate for stomach cancer is 78.6% (National Cancer Registration Statistics 2019–2023, National Cancer Center Korea). Over the same period, the 5-year relative survival rate for all cancers combined is 73.7%.
• In the U.S. SEER data (2016–2022), the 5-year relative survival rate for stomach cancer is 39.8%; both figures are nationwide statistics, not the results of any single hospital.
• Early-stage stomach cancer (confined to the mucosa) can often be treated with endoscopic submucosal dissection (ESD), completing treatment without removing the stomach.
• Operable stomach cancer (roughly stages 1–3) is typically treated with subtotal or total gastrectomy plus lymph node dissection, with perioperative chemotherapy added for stages 2–3.
• Survival rates are population averages, not predictions for any individual outcome, and vary significantly depending on stage, histologic type, age, and coexisting conditions.

Why do the stomach cancer survival figures differ between Korea and the U.S.?

• The difference in figures comes not just from treatment technology but largely from how early the cancer is detected. Because Korea offers a national screening program with gastroscopy every two years starting at age 40, a higher proportion of cases are diagnosed at an early stage.
• Korea's 78.6% (National Cancer Registration Statistics 2019–2023) and the U.S.'s 39.8% (SEER 2016–2022) are both nationwide statistics, not the treatment outcomes of any particular hospital. Korean medical law restricts the use of hospital-specific outcome data in advertising.
• Statistical differences cannot be read directly as individual outcomes, and even within the same stomach cancer diagnosis, treatment goals and methods differ completely depending on the stage range.

How do treatment and outcomes differ by stage?

• In the TNM staging system, T indicates how deeply the cancer has invaded the layers of the stomach wall, N indicates the extent of lymph node involvement, and M indicates whether there is distant organ spread. Stage 1 is confined to shallow wall layers with little or no lymph node involvement; stages 2–3 involve deeper wall invasion or lymph node spread; stage 4 means spread to distant organs.
• For early-stage stomach cancer (confined to the mucosa) that is small, well-differentiated, and without ulceration, endoscopic submucosal dissection (ESD) can remove just the lesion, preserving the stomach and allowing near-normal eating and daily life afterward.
• For operable stages 1–3, subtotal or total gastrectomy with surrounding lymph node dissection is the standard treatment. Among the three surgical approaches—open, laparoscopic, and robotic—laparoscopic and robotic surgery tend to cause less pain and scarring, allowing faster recovery. For stages 2–3, adjuvant chemotherapy is added after surgery, or neoadjuvant chemotherapy is given beforehand to shrink the tumor prior to surgery.
• For stage 4 or recurrent disease, the treatment goal shifts from cure to control. Depending on biomarker results such as HER2, PD-L1, and CLDN18.2, targeted therapies or immune checkpoint inhibitors are now part of the standard approach added to chemotherapy.

What is the sequence of recovery and follow-up after surgery?

• Step 1 — Diagnosis: Gastroscopy and biopsy confirm whether cancer is present and determine the histologic type, while abdominal and chest CT assess the depth of wall invasion and whether there is lymph node or distant spread.
• Step 2 — Staging: For early-stage cancer, endoscopic ultrasound is added; for advanced or metastatic cancer, biomarker tests such as HER2, PD-L1, and MSI determine which drugs will be used.
• Step 3 — Treatment: Depending on the stage, the appropriate option is chosen among endoscopic resection, gastrectomy (open, laparoscopic, or robotic), and chemotherapy.
• Step 4 — Recovery: After gastrectomy, patients learn to eat smaller, more frequent meals. Dumping syndrome and deficiencies in iron or vitamin B12 can occur, requiring regular nutritional monitoring. Return to daily life typically happens gradually over several weeks to two to three months after surgery.
• Step 5 — Follow-up: Monitoring is frequent during the first 2–3 years and then spaced out through year 5, with repeated clinical exams, blood tests, CT scans, and gastroscopy. For patients who underwent endoscopic resection, the interval of follow-up gastroscopy is especially important to check for new lesions in the remaining stomach.

FAQ — If the entire stomach is removed, how should I eat for the rest of my life?

You will need to switch to eating smaller amounts more frequently rather than large meals at once. The first few months tend to be the hardest, and most people adjust afterward. Dumping syndrome—dizziness and sweating after eating—along with iron or vitamin B12 deficiency can occur, so regular monitoring is necessary.

FAQ — Whose results does this survival rate represent?

This is a nationwide statistic for Korea as a whole, not the outcome of any specific hospital (National Cancer Registration Statistics 2019–2023, National Cancer Center Korea). Under Korean medical law, hospital-specific outcomes are not used in advertising, and actual treatment results vary by individual depending on stage and overall health condition.

FAQ — Can endoscopy and CT results obtained locally be used for remote review (pre-arrival review)?

Yes. If you submit imaging (original DICOM files), biopsy results, and a diagnostic report, medical staff in the relevant specialty will review them and provide a written opinion. The remote review (pre-arrival review) fee of KRW 1,000,000 is a fixed amount and is deducted from treatment costs if you proceed to contract for treatment. If additional tests are needed, this will be specified in the written opinion.

Sources and Notes

• This article was written based on National Cancer Registration Statistics 2019–2023 (National Cancer Center Korea), SEER 2016–2022 (U.S. National Cancer Institute), the National Cancer Information Center, and general explanations at the level of NCCN patient guidelines.
• This content is intended for general medical information purposes only. Diagnosis, treatment methods, and outcomes may vary depending on individual circumstances. Accurate diagnosis and treatment decisions should always be made in consultation with medical professionals.